All faculty, staff, and students throughout the Mount Sinai Health System are expected to get an annual influenza vaccination, a request that has new urgency this year. For the first time, the New York State Department of Health is requiring that all hospital personnel either receive the influenza vaccination or wear masks in areas where there is potential for patient contact, including lobbies, corridors, elevators, and cafeterias, as well as in all typical patient-care areas. This new regulation will be in effect throughout the influenza season, which typically runs from December to late spring.
Research in Mark Baxter’s laboratory, the Glickenhaus Laboratory of Neuropsychology, focuses on the neural systems underlying memory and other higher cognitive functions, and understanding how disturbances in these systems impair cognitive function in brain disorders. Our general approach is to study the effects on behavior of specific manipulations of neural circuits in animal models, to gain insight into how similar disruptions in human disease may be responsible for cognitive impairment.
Mount Sinai’s Gastrointestinal Medical Oncology practice has been recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO). The QOPI® Certification Program provides a 3-year certification for outpatient hematology-oncology practices that meet the highest standards for quality cancer care.
QOPI certification signifies that an outpatient oncology practice has met core standards in a variety of areas that affect the quality of patient care, including staff training and education, chemotherapy orders and drug preparation, patient consent and education, safe chemotherapy administration, and monitoring and assessment of patient well-being. Mount Sinai is the first site in Manhattan to receive QOPI-certification.
Ten faculty members were named endowed professors at the 2013 Convocation Ceremony on Monday, September 30, an event that marks the beginning of the academic year for the Icahn School of Medicine at Mount Sinai. The honorees, renowned in their respective fields—including allergy and immunology, cancer research, neuroscience, nephrology, otolaryngology, translational genetics, and transplant immunology—comprised the largest group named at one time at Mount Sinai.
The Emergency Departments at St. Luke’s and Roosevelt Hospitals started transferring pediatric cases to The Mount Sinai Hospital on Tuesday, October 1, a day after the creation of the Mount Sinai Health System. These patient transfers are among the first systemwide synergies to be implemented throughout the seven campuses, and point to the fluidity of the Health System’s Inter-Hospital Transfer Center, which is open seven days a week, 24 hours a day.
It was standing room only at the campuses of Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, and New York Eye and Ear Infirmary for a series of Town Hall meetings at which the leaders of the Mount Sinai Health System presented their vision for the future and how the new system will address today’s health care challenges.
In recent years there have been major breakthroughs in the identification of novel molecular and cellular mechanisms underlying the pathophysiology of brain disorders. For instance, thanks to state-of-the-art molecular techniques, current stem cell research not only allows in-vitro recapitulation of disease expression, but also for the discovery of novel disease-associated cellular mechanisms.
As of September 11th 2013, BOTOX™ Cosmetic (onabotulinumtoxinA) received approval from the FDA for the treatment of lines extending around the corner of the eyes, commonly known as “crow’s feet.” Since its initial FDA approval in 2002, Botox has become incredibly popular for the treatment of facial lines and wrinkles, both on label (glabellar lines – the dreaded “11” seen between the eyebrows) and off-label (all the other lines and wrinkles on your face, including crows feet). Botox, along with its competitors and Dysport™ and Xeomin, are often referred to as “relaxing agents.” Technically, they are paralytic agents produced from sterile derivatives of Botulinum Toxin but most patients prefer not associate Botulism, toxins or paralysis with their face.
Liver cancer may be less well-known than other cancer types, but it is the fifth most common cancer in the world. And despite progress in other fields, liver cancer is one of the few cancers whose rate in the United States is continuing to rise. Liver cancer, whose medical term is hepatocellular carcinoma, is tumor that starts in the liver and can spread to other organs if left untreated.